The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; Amgen; Argos Therapeutics; Astellas Pharma; Bristol-Myers Squibb; Celgene; Eisai; Exelixis; Genentech/Roche; Medivation; Merck
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CVS; Emmaus Medical INC.; Kiowa Kirin; Seagen; Stemline Therapeutics
Speakers' Bureau - Celgene; Genentech/Roche; Sanofi Pasteur
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Argos Therapeutics; Celgene; Emmaus Medical INC.; Genentech; Merck; Seagen; Stemline Therapeutics
 
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Calithera Biosciences (Inst); Clinigen Group (Inst); Jounce Therapeutics (Inst); Merck (Inst); Nektar (Inst); Peloton Therapeutics (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Bristol-Myers Squibb
FRACTION-RCC: Innovative, high-throughput assessment of nivolumab + ipilimumab for treatment-refractory advanced renal cell carcinoma (aRCC).
 
Toni K. Choueiri
Employment - Dana Farber Cancer Hospital
Leadership - ASCO; Dana Farber Cancer Hospital; Kidney Cancer Association; KidneyCan; NCCN
Stock and Other Ownership Interests - Pionyr; Tempest Therapeutics
Honoraria - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Foundation Medicine; Genentech/Roche; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Consulting or Advisory Role - Alexion Pharmaceuticals; alligent; Analysis Group; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Analysis Group (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Cerulean Pharma (Inst); Congressionally Directed Medical Research Programs (DOD) (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Exelixis (Inst); Foundation Medicine (Inst); Gateway for Cancer Research (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NCI (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Prometheus (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel
 
Harriet M. Kluger
Consulting or Advisory Role - Array BioPharma; Biodesix; Celldex; Corvus Pharmaceuticals; Genentech/Roche; Immunocore; Iovance Biotherapeutics; Merck; Nektar; Pfizer
Research Funding - Apexigen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Apexigen
 
Saby George
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; EMD Serono; Exelixis; Genentech/Roche; Janssen Oncology; Pfizer; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals (Inst); Eisai (Inst); Immunomedics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
 
Scott S. Tykodi
No Relationships to Disclose
 
Timothy M. Kuzel
No Relationships to Disclose
 
Ruth Perets
Consulting or Advisory Role - BioLineRx; Kadmonopharm Theraputics
 
Suresh Nair
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Nektar (Inst)
 
Giuseppe Procopio
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Sharp & Dohme; Novartis; Pfizer
 
Michael Anthony Carducci
Consulting or Advisory Role - Abbvie; Astellas Pharma; Foundation Medicine; Pfizer; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Gilead Sciences (Inst); pfizer (Inst)
 
Vincent Castonguay
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Celgene; Janssen; Novartis
 
Edmund Folefac
No Relationships to Disclose
 
Chung-Han Lee
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Calithera Biosciences; Eisai
 
Sebastien J. Hotte
Honoraria - Astellas Scientific and Medical Affairs Inc; Bayer; Eisai; Janssen Oncology; Merck
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Pfizer; Roche Canada
Research Funding - Astellas Pharma; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Clovis Oncology; Janssen Oncology; Merck; Pfizer (Inst); Roche/Genentech; Seagen
Travel, Accommodations, Expenses - Eisai
 
Wilson H. Miller
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; Merck; Merck; Novartis; Novartis; Roche; Roche
Consulting or Advisory Role - Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; GlaxoSmithKline; GlaxoSmithKline; Merck; Merck; Novartis; Novartis; Roche; Roche
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); GlaxoSmithKline (Inst); GlaxoSmithKline (Inst); MedImmune (Inst); MedLM (Inst); Merck (Inst); Merck (Inst); MethylGene (Inst); MethylGene (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst)
 
Shruti S. Saggi
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
David Gold
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Genentech/Roche; Incyte; Lilly; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Novartis (Inst); Pfizer (Inst)
 
Bernard Escudier
Honoraria - Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Oncorena; Pfizer; Roche/Genentech
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EUSA Pharma; Ipsen; Novartis; Pfizer; Roche/Genentech
Research Funding - Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche/Genentech